MNTA Stock Recent News Momenta Pharmaceuticals (MNTA) 10.63 11/14/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 10:50 PM

Momenta Pharmaceuticals (MNTA) 10.63 $MNTA

Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 6:39PM CST

MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Thu Nov 06, 7:42AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:15PM CST

MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 71.75 (-0.33), TEVA: 57.07 (-0.10), ABBV: 64.00 (+0.37), SNY: 46.68 (+0.15), MNTA: 10.63 (+0.09), NVS: 93.95 (-0.43)

Momenta updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:03AM CST

MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals (MNTA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST

MNTA: 10.63 (+0.09)

Momenta misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 8:09AM CST
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Wednesday reported a third-quarter loss of $29.1 million.
MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:04AM CST

MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Wed Nov 05, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the third quarter ended September 30, 2014.
MNTA: 10.63 (+0.09)

Notable earnings before Wednesday’s open
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:30PM CST

MDLZ: 38.16 (-0.07), CSTE: 59.37 (+0.15), FSS: 15.65 (+0.06), HL: 2.52 (+0.22), BBEP: 15.55 (+0.66), RRD: 16.93 (-0.13), CNP: 24.04 (-0.15), INXN: 28.28 (-0.32), OGE: 36.35 (-0.08), MNTA: 10.63 (+0.09), GLDD: 7.23 (+0.11), AXAS: 4.07 (+0.16), MEMP: 16.37 (+1.01), PWE: 4.22 (+0.16), ROC: 79.19 (+0.46), SSYS: 104.85 (+3.74), DNR: 11.20 (+0.21), MVIS: 1.70 (+0.02), PWR: 33.16 (-0.49), COV: 93.98 (+0.31), SMG: 60.60 (+0.27), SEP: 56.36 (+0.36), CLH: 48.95 (+0.39), ATHM: 44.58 (+1.59), STWD: 23.52 (+0.02), BPI: 11.26 (+0.26), LVLT: 49.04 (+0.40), AVA: 33.46 (-0.45), MGA: 103.92 (+0.53), BSFT: 27.50 (+0.05), EE: 37.55 (-0.18), CTSH: 53.28 (-0.11), DAVE: 25.75 (+0.15), NRG: 31.31 (-0.24), CEQP: 8.46 (-0.12), ACT: 243.77 (+2.14), AWR: 34.24 (-0.21), DUK: 79.11 (+0.12), LAMR: 52.55 (-0.01), CCC: 21.22 (+0.05), HFC: 42.83 (+0.04), RTI: 23.62 (+0.60), CHK: 23.21 (+0.50), NUS: 39.40 (-0.32), NICE: 46.42 (+0.02), HRC: 44.76 (-0.27), ENDP: 66.26 (-0.84), SE: 38.12 (+0.26), CBB: 3.47 (+0.06), GTN: 10.11 (+0.39), ANSS: 79.79 (+0.50), RLGY: 42.97 (+0.37), ENB: 45.37 (-0.07), SBGI: 28.09 (+0.74), ARIA: 6.15 (-0.10), LPX: 14.61 (-0.29), RDC: 23.75 (-0.01), KELYA: 15.42 (+0.01)

Momenta reports November 5
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:59AM CDT

MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Wed Oct 22, 8:43AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2014 before the U.S. financial markets open on Wednesday, November 5, 2014.
MNTA: 10.63 (+0.09)

Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.07 (-0.47), CGEN: 6.55 (-0.07), TEVA: 57.07 (-0.10), AMPE: 3.34 (-0.04), MNTA: 10.63 (+0.09), NVS: 93.95 (-0.43)

Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.66 (-0.17), NPSP: 29.00 (-0.78), MNTA: 10.63 (+0.09), ARNA: 4.53 (-0.08), XOMA: 3.92 (-0.05)

Why Teva Pharmaceutical (TEVA) Stock Is Falling Today
at The Street - Wed Oct 15, 1:53PM CDT
Teva Pharmaceutical Industries (TEVA) stock is lower as the company faces uncertainty as U.S Supreme Court hears a patent case about its best selling drug Copaxone.
MYL: 54.05 (-0.68), TEVA: 57.07 (-0.10), MNTA: 10.63 (+0.09), NVS: 93.95 (-0.43)

Supreme Court weighs generic drug dispute
By SAM HANANEL - AP - Wed Oct 15, 12:51PM CDT
WASHINGTON (AP) — The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
MYL: 54.05 (-0.68), TEVA: 57.07 (-0.10), MNTA: 10.63 (+0.09)

Momenta Pharmaceuticals (MNTA) in Focus: Stock Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:25AM CDT
Momenta Pharmaceuticals (MNTA) was a big mover last session, with shares rising nearly 6% on the day.
MYGN: 32.84 (-0.51), HALO: 8.54 (-0.20), LGND: 57.79 (-0.17), MNTA: 10.63 (+0.09)

Wall Street Breakfast: Chinese CPI Slips To Lowest In Almost 5 Years
Wall Street Breakfast - Seeking Alpha - Wed Oct 15, 5:33AM CDT
Economy Chinese inflation dropped to an almost five-year low in September, tumbling to 1.6% on year from 2% in August and coming in below consensus of 1.7%. Factory gate prices (PPI) slumped 1.8% vs -1.2% previously. "You got...
MYL: 54.05 (-0.68), TM: 119.82 (unch), INTC: 33.95 (+0.27), HPQ: 36.92 (+0.56), MNTA: 10.63 (+0.09), PERY: 23.58 (+0.63), SPY: 204.24 (+0.05), QQQ: 103.22 (+0.32), SHPG: 202.62 (+0.20), QCOM: 70.85 (+0.20), TEVA: 57.07 (-0.10), ABBV: 64.00 (+0.37), EMC: 30.05 (+0.63), MDW: 0.68 (+0.06), STO: 22.10 (+0.53), NVS: 93.95 (-0.43)

Teva due to appear in Supreme Court over Copaxone patent
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 3:13AM CDT

MYL: 54.05 (-0.68), TEVA: 57.07 (-0.10), MNTA: 10.63 (+0.09), NVS: 93.95 (-0.43)

Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:30AM CDT
Momenta Pharmaceuticals saw a big move last session, as the company’s shares fell by almost 14% on the day.
MACK: 8.48 (+0.09), EBS: 24.22 (-0.10), LGND: 57.79 (-0.17), MNTA: 10.63 (+0.09)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

When Families Should Consider Life Insurance Plans

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Greenland Energy Board Reshuffle: McIllree Exits

A Change in Greenland Energy's Lineup Well, folks, the wheel keeps turning at Greenland Energy Company (NASDAQ:GLND). Roderick McIllree has decided to step off the Board of Directors' carousel, effective immediately. And nope, there wasn't a classic showdown or any disagreement on the table. This exit is as drama-free as they come—just him stepping aside, leaving the...

Tampa General's Tech Triumphs in Healthcare Innovation

Spotlight on Tampa General's Technological Edge Wow, just when you think you've seen it all in the healthcare sector, here comes Tampa General Hospital (TGH) shaking things up again. Making waves by earning a spot among the "World's Best Smart Hospitals for 2027" by Newsweek and Statista, TGH's proving that tech-savvy isn't just for Silicon Valley startups. Folks, being...

Unicycive Faces Legal Heat: Investors Eye Key Deadline

What Went Wrong with Unicycive? Unicycive Therapeutics, Inc., a player in the biotech space, finds itself embroiled in a legal quagmire. A class action lawsuit is hovering over NASDAQ:UNCY, spurred by allegations of the company's slip-ups in manufacturing oversight. Investors are ticked off, understandably, as the lawsuit zeroes in on failures to resolve FDA-cited issues....

College Athletics Needs a New Business Revolution

Wake Up Call for College Athletics Here's a heads-up—college sports aren't just about cheering fans and game-day jerseys anymore. It's high time universities start thinking of athletics as businesses, blending the thrill of game day with the realities of financial statements. Michael Schreiber rang this bell loud and clear on the 'Disruption Interruption' podcast,...

French Florist Blossoms in Los Gatos This October

A New Floral Journey Blooms in Los Gatos October's shaping up to be a vibrant month for Los Gatos, as a slice of French elegance arrives courtesy of Anhelina Baftalovska. She's not just bringing flowers; she's introducing a unique blend of life passions and entrepreneurial spirit to the community. Let's dig into this delightful story of blooms and business. A Ukrainian's...

Corra Group Enhances Hiring with Digital I-9 Services

The Changing Landscape of Employment Verification Employment verification is no longer a mere formality with a paper form. Now, it’s a digital jungle, where missing a deadline isn't just a slap on the wrist, but a compliance nightmare. In steps Corra Group, bringing electronic I-9 tools to the frontlines, geared to help employers juggle the mess of forms, deadlines, and...

Venture Dock Fosters Global Startup Ecosystems

Venture Dock Connects the Global Startup Dots When it comes down to bridging the gap between promising innovation and commercial success, you'd be hard-pressed to find a better player than Venture Dock. In a world filled with buzzwords and fluff, these guys are socketed deep in the guts of genuine startup development — and they're making waves with their recent...

Ecopetrol Ushers New Executive Leadership for Transition

New Blood Steering the Energy Transition Let's crack open the vault on Ecopetrol's recent maneuver: Armando José Cuello Navarro is stepping up as the new Executive Vice President of Energy Transition. It's like handing the wheel to a seasoned driver in a storm—this guy’s got the chops to navigate Colombia's energy maze. Cuello's resume reads like a textbook on energy...

Visteon Reports Q3 2026 Results with Mixed Signals

Visteon's Q3 2026 Financial Performance: Insights and Implications You'd think by now that anything to do with supply chain hiccups wouldn’t surprise me, but Visteon Corporation’s recent third quarter results got my gears grinding yet again. Here's the scoop: Visteon pulled in $970 million in sales, strutting around with a 10% growth-over-market. Their resilience...